ストックスクリーナーアプリを入手
31.02
1.80%
-0.57
アフターアワーズ：
31.02
Cogent Biosciences Inc (COGT) 最新ニュース
Insiders At Cogent Biosciences Sold US$12m In Stock, Alluding To Potential Weakness - Moomoo
Cogent Biosciences, Inc. (COGT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA - Yahoo Finance
Why (COGT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance - Yahoo Finance
Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative? - Yahoo Finance
Cogent Biosciences (COGT) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Cogent Biosciences (COGT) Stock Price, News & Analysis - Stock Titan
Cogent Biosciences, Inc. (COGT) Stock Analysis: Unveiling A Potential 68% Upside - DirectorsTalk Interviews
Should FDA Filing Acceptance Require Action From Cogent Biosciences Stock Investors? - simplywall.st
Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years - Benzinga
COGT Reiterates by Wedbush -- Price Target Maintained at $55 - GuruFocus
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with Advanced Systemic Mastocytosis - Investing News Network
COGT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $55 - GuruFocus
Cogent Biosciences (COGT) FDA NDA Acceptance Highlights High P/S Valuation Amid Mixed Insider and Guru Activity - GuruFocus
FDA Accepts Cogent Biosciences' NDA for Bezuclastinib, COGT Trad - GuruFocus
Cogent Bio wins third FDA review for lead asset (COGT:NASDAQ) - Seeking Alpha
A drug trial found responses in 65% of patients. The FDA will review it. - Stock Titan
Liquidity Mapping Around (COGT) Price Events - Stock Traders Daily
Cogent Biosciences (COGT) Edges Lower to $34.08 as Shares Consolidate Below Key ResistanceRectangle Pattern - dars.gov.et
Cogent Biosciences Stock Price Forecast. Should You Buy COGT? - StockInvest.us
How (COGT) Movements Inform Risk Allocation Models - Stock Traders Daily
Cogent Biosciences (COGT) Edges Higher as Buyers Defend Key Support ZoneCall Wall - dars.gov.et
Cogent Biosciences Inc. (COGT) Peer Comparison – Compare with Others - Value Research
Cogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCiencia - marketscreener.com
Cogent Biosciences (COGT) inks 5-year drug manufacturing pact - Stock Titan
Cogent Biosciences director Arlene Morris sells $1.69m shares By Investing.com - Investing.com India
$100 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today - Benzinga
Cogent Biosciences Insider Sold Shares Worth $1,689,493, According to a Recent SEC Filing - marketscreener.com
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress - Barchart.com
Cogent Biosciences (COGT) Slides 6.5% to $34.67 as Support and Resistance Levels Come into FocusETF Premium Discount - dars.gov.et
Cogent Biosciences Inc. (COGT) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cogent Biosciences Inc. (COGT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat (NASDAQ:COGT) - Seeking Alpha
Cogent (COGT) Earnings Report: EPS Falls Short of Its Estimate in the Current Update; After Results: Shares Fall 0.91% in the Latest SessionAnalyst Earnings Estimate - vinanet.vn
Cogent (COGT) Earnings Reading: The Available Earnings Metric Delivers a Miss on the Day; Price Move - vinanet.vn
Cogent (COGT) Earnings Report: EPS Falls Short of Its Estimate in the Current Update; After Results - careplusvn.com
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Cogent Biosciences (COGT) Q2 Update Highlights Valuation Challenges Amid Strong Cash Reserves - GuruFocus
Has Cogent Biosciences (COGT) Run Too Far After Wider Losses? - Sahm
Cogent (COGT) Q1 2026 Earnings: EPS Misses Its Estimate in the Latest Session; Investor Response - careplusvn.com
COGT Maintained by Piper Sandler -- Price Target Raised to $55 - GuruFocus
Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next - simplywall.st
Discipline and Rules-Based Execution in COGT Response - Stock Traders Daily
Bank of America Corp DE Has $40.18 Million Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences | ARS: Annual Report to Security Holders - Moomoo
Deerfield group discloses 2.88% Cogent Biosciences (COGT) position in amended 13G - Stock Titan
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
COGT Maintains Buy Rating by Guggenheim -- Price Target Raised t - GuruFocus
Guggenheim raises Cogent stock price target to $52 on FDA decisions - Investing.com
Tema ETFs LLC Acquires 64,898 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Shares Down 5.7%Should You Sell? - MarketBeat
Cogent Biosciences (COGT) Slides 6.81% to $38.70 as Biotech Risk-Off IntensifiesWave Extension - careplusvn.com
Cogent Biosciences Q2 Loss Widens - Moomoo
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results - Investing News Network
Cogent BiosciencesMay Offer Up To $400 Million In Common Stock Through Guggenheim Securities - TradingView
Cogent Biosciences (COGT) files prospectus for $400M at-the-market stock program - Stock Titan
Cogent Biosciences (NASDAQ: COGT) details cash runway and bezuclastinib FDA timelines - Stock Titan
Cogent Biosciences (NASDAQ:COGT) Shares Gap DownTime to Sell? - MarketBeat
Cogent Biosciences set to report earnings ahead of FDA decisions By Investing.com - Investing.com Canada
0.05%
0.82%
大文字化:
|
ボリューム (24 時間):